Wang Li, Luo Jiang-Yun, Li Bochuan, Tian Xiao Yu, Chen Li-Jing, Huang Yuhong, Liu Jian, Deng Dan, Lau Chi Wai, Wan Song, Ai Ding, Mak King-Lun Kingston, Tong Ka Kui, Kwan Kin Ming, Wang Nanping, Chiu Jeng-Jiann, Zhu Yi, Huang Yu
Institute of Vascular Medicine, Shenzhen Research Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China.
School of Biomedical Sciences, Chinese University of Hong Kong, Hong Kong, China.
Nature. 2016 Dec 22;540(7634):579-582. doi: 10.1038/nature20602. Epub 2016 Dec 7.
The Yorkie homologues YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif, also known as WWTR1), effectors of the Hippo pathway, have been identified as mediators for mechanical stimuli. However, the role of YAP/TAZ in haemodynamics-induced mechanotransduction and pathogenesis of atherosclerosis remains unclear. Here we show that endothelial YAP/TAZ activity is regulated by different patterns of blood flow, and YAP/TAZ inhibition suppresses inflammation and retards atherogenesis. Atheroprone-disturbed flow increases whereas atheroprotective unidirectional shear stress inhibits YAP/TAZ activity. Unidirectional shear stress activates integrin and promotes integrin-Gα interaction, leading to RhoA inhibition and YAP phosphorylation and suppression. YAP/TAZ inhibition suppresses JNK signalling and downregulates pro-inflammatory genes expression, thereby reducing monocyte attachment and infiltration. In vivo endothelial-specific YAP overexpression exacerbates, while CRISPR/Cas9-mediated Yap knockdown in endothelium retards, plaque formation in ApoE mice. We also show several existing anti-atherosclerotic agents such as statins inhibit YAP/TAZ transactivation. On the other hand, simvastatin fails to suppress constitutively active YAP/TAZ-induced pro-inflammatory gene expression in endothelial cells, indicating that YAP/TAZ inhibition could contribute to the anti-inflammatory effect of simvastatin. Furthermore, activation of integrin by oral administration of MnCl reduces plaque formation. Taken together, our results indicate that integrin-Gα-RhoA-YAP pathway holds promise as a novel drug target against atherosclerosis.
约克郡同源物YAP(Yes相关蛋白)和TAZ(具有PDZ结合基序的转录共激活因子,也称为WWTR1)是Hippo信号通路的效应器,已被确定为机械刺激的介质。然而,YAP/TAZ在血流动力学诱导的机械转导和动脉粥样硬化发病机制中的作用仍不清楚。在这里,我们表明内皮细胞YAP/TAZ活性受不同血流模式的调节,抑制YAP/TAZ可抑制炎症并延缓动脉粥样硬化的发生。易致动脉粥样硬化的紊乱血流会增加YAP/TAZ活性,而具有抗动脉粥样硬化作用的单向剪切应力则会抑制YAP/TAZ活性。单向剪切应力激活整合素并促进整合素与Gα的相互作用,导致RhoA抑制以及YAP磷酸化和抑制。抑制YAP/TAZ可抑制JNK信号传导并下调促炎基因的表达,从而减少单核细胞的黏附和浸润。在体内,内皮细胞特异性YAP过表达会加剧动脉粥样硬化,而通过CRISPR/Cas9介导的内皮细胞Yap基因敲低则会延缓ApoE小鼠的斑块形成。我们还发现几种现有的抗动脉粥样硬化药物,如他汀类药物,可抑制YAP/TAZ的反式激活。另一方面,辛伐他汀未能抑制内皮细胞中组成型活性YAP/TAZ诱导的促炎基因表达,这表明抑制YAP/TAZ可能有助于辛伐他汀的抗炎作用。此外,口服MnCl激活整合素可减少斑块形成。综上所述,我们的结果表明整合素-Gα-RhoA-YAP信号通路有望成为抗动脉粥样硬化的新型药物靶点。